IMMUNOHISTOCHEMICAL DIAGNOSTICS OF PROGRAMMED DEATH-LIGAND-1 AND CYCLOOXYGENASE-2 RECEPTORS IN CERVICAL NEOPLASIA: POSSIBILITIES OF A DIFFERENTIATED APPROACH

Authors

  • I.F. Soltanova Azerbaijan Medical University

DOI:

https://doi.org/10.34921/amj.2021.3.016

Keywords:

cervical cancer, cervical dysplasia, CIN (cervical intraepithelial neoplasia), PDL-1 (programmed death-ligand), COX-2 (cyclooxygenase)

Abstract

The article examines the relationship between different degrees of cervical dysplasia (3 severity - CIN I, II and III), programmed cell death ligand-1 (PD-L1) and cyclooxygenase-2 (COX-2) receptors. was informed about. Immunohistochemical examination using antibodies against PD-L1 and COX-2 receptors was performed in the biopsies of 35 patients with CIN I, II and III diagnoses. Evaluation of PD-L1 reaction results was determined on the basis of the share of stained cells in the total population - less than 1% negative, more than 1% positive. The results of the COX-2 reaction are 0 or negative, depending on the staining; Rated as 1+ (weak), 2+ (mild) and 3+ (severe). The study found that PD-L1 and COX-2 receptor levels vary depending on the degree of dysplasia. Thus, while no PD-L1-positive (+) cases were reported during CIN I, the response was positive in most patients during CIN III. The results of COX-2 staining showed that the proportion of cases where dysplasia is already severe staining is increasing. Thus, the study found that high-grade dysplasias are characterized by PD-L1-positivity and severe COX-2-expression. The obtained results can be used in the formation of the algorithm of the therapeutic approach to UBD and in determining the volume of surgical excision, as well as to optimize the prognostic assessment of cervical neoplasms.

Downloads

Download data is not yet available.

Published

2021-09-30

How to Cite

Soltanova , I. (2021). IMMUNOHISTOCHEMICAL DIAGNOSTICS OF PROGRAMMED DEATH-LIGAND-1 AND CYCLOOXYGENASE-2 RECEPTORS IN CERVICAL NEOPLASIA: POSSIBILITIES OF A DIFFERENTIATED APPROACH. Azerbaijan Medical Journal, (3), 116–121. https://doi.org/10.34921/amj.2021.3.016

Issue

Section

CLINICAL RESEARCH